Last reviewed · How we verify
NCT05198570
Pharmacokinetics of Intravenous Acyclovir in Oncologic Paediatric Patients
trial testing Pharmacokinetic analysis in Herpesviridae Infections in 200 participants. Currently enrolling.
31 December 2025
Quick facts
| Lead sponsor | University of Pisa |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 200 |
| Start date | 15 September 2021 |
| Primary completion | 31 December 2025 |
| Estimated completion | 31 March 2026 |
| Sites | 1 location across Italy |
Drugs / interventions tested
- Pharmacokinetic analysis
Conditions studied
- Herpesviridae Infections — all drugs for Herpesviridae Infections →
- Herpes Simplex 1 — all drugs for Herpes Simplex 1 →
- Varicella Zoster Virus Infection — all drugs for Varicella Zoster Virus Infection →
- Transplantation Infection — all drugs for Transplantation Infection →
Sponsor
University of Pisa
Who can join
Adults 6 Months to 18, any sex, with Herpesviridae Infections or Herpes Simplex 1. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
* Herpesvirus infections may be severe in immunocompromised patients, with a high risk of complications and mortality. * Recipients of hematopoietic stem cell transplant (HSCT) or patients receiving high-intensity chemotherapy for hematological malignancies are the most vulnerable individuals. * Although the worldwide prevalence of herpes simplex virus 1 (HSV-1) and varicella-zoster virus (VZV), antiviral prophylaxis in seropositive HSCT recipients has significantly reduced the rate of infection. * Acyclovir (ACV) is the first-choice drug for the prophylaxis or the therapy of that kind of infection. * Since the beginning, ACV has demonstrated to be characterized by a large interpatient variability, especially in children. * Therefore, therapeutic drug monitoring and pharmacokinetic studies may help in optimizing drug in children with malignancies.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Population Pharmacokinetics of Intravenous Acyclovir in Oncologic Pediatric Patients.
Maximova N, Nisticò D, Luci G, Simeone R, et al · · 2022 · cited 3× · PMID 35496277 · DOI 10.3389/fphar.2022.865871
Verify or expand the search:
- PubMed search for NCT05198570
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Pharmacokinetic analysis
Trials testing the same drug.
- NCT03718104 — MOM NEST Study: Maternal Opioid Medication: Naltrexone Efficacy Study · completed
Other University of Pisa trials
Trials by the same sponsor.
- NCT07520890 — Oral Biopsy Bleeding in Patients on Direct Oral Anticoagulants (DOACs) · recruiting
- NCT07444229 — Team-Based Learning Integrated Into Clinical Simulation in Nursing Students · NA · not yet recruiting
- NCT07041983 — 24-h Energy Expenditure and Anti-obesity Medication · enrolling by invitation
- NCT07510685 — Closed-System Bladder Irrigation to Reduce Urinary Tract Infections After Endoscopic Urologic Surgery (IRIS Trial) · NA · completed
- NCT07055152 — Retinal OCTA for Microvascular Dysfunction Evaluation and Outcome Prediction in MINOCA Patients · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05198570 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Pisa
- Last refreshed: 4 June 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05198570.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing